Fig. 2: Kaplan–Meier estimates of PFS and OS. | Nature Medicine

Fig. 2: Kaplan–Meier estimates of PFS and OS.

From: Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial

Fig. 2

a, Kaplan–Meier curve of PFS per BICR in patients treated with SG (n = 166) versus chemotherapy (n = 165). b, Kaplan–Meier curve of PFS per INV in patients treated with SG versus chemotherapy. c, Kaplan–Meier curve of OS in patients treated with SG versus chemotherapy. The median PFS and OS were calculated using the Kaplan–Meier method. The HR values were estimated using a stratified Cox proportional-hazards model, and the P values were calculated using a stratified log-rank test. Dashed blue and grey lines indicate median values, and dashed black lines indicate landmark time points. aStratified log-rank P value. NE, not estimable.

Back to article page